An HLA-DR-degenerate epitope pool detects insulin-like growth factor binding protein 2-specific immunity in patients with cancer

Kimberly R. Kalli, Christopher J. Krco, Lynn C. Hartmann, Karin Goodman, Matthew J. Maurer, Chao Yu, Elliot M. Johnson, Courtney L. Erskine, Mary L. Disis, Peter J. Wettstein, John D. Fikes, Melanie Beebe, Glenn Ishioka, Keith L Knutson

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Recent studies have shown the importance of helper CD4 T cells in initiating and sustaining tumor-specific CD8 T-cell immunity. This has paved the way for identifying MHC class II epitopes that could be incorporated into class I-based vaccines. In this study, the goal was to identify an HLA-DR-degenerate epitope pool derived from insulin-like growth factor binding protein 2 (IGFBP-2). IGFBP-2, a regulator of insulin-like growth factor action, is overexpressed in the majority of breast and ovarian cancers. Using algorithms, we predicted 29 HLA-DR1-binding epitopes. Binding assays targeting 15 different HLA-DRs revealed that 10 epitopes were degenerate, binding to at least four different HLA-DR variants. An IFN-γ enzyme-linked immunosorbent spot assay was used to assess immunity to these 10 epitopes in 48 patients with either breast or ovarian cancer and 18 controls. Elevated Tcell immunity in patients was detected in 4 of the 10 epitopes (IGFBP2.17, IGFBP2.22, IGFBP2.249, and IGFBP2.293). The cumulative T-cell frequency of these four epitopes was elevated in patients relative to controls. All four peptides are naturally processed and presented to CD4 T-cells. The degenerate pool of peptides covers nearly 80% of patients and may be useful for augmenting CD4 T-cell immunity in patients undergoing immunization.

Original languageEnglish (US)
Pages (from-to)4893-4901
Number of pages9
JournalCancer Research
Volume68
Issue number12
DOIs
StatePublished - Jun 15 2008

Fingerprint

Insulin-Like Growth Factor Binding Protein 2
HLA-DR Antigens
Epitopes
Immunity
Neoplasms
T-Lymphocytes
Ovarian Neoplasms
HLA-DR1 Antigen
Breast Neoplasms
Peptides
Somatomedins
Helper-Inducer T-Lymphocytes
Immunization
Vaccines
Enzyme-Linked Immunosorbent Assay

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

An HLA-DR-degenerate epitope pool detects insulin-like growth factor binding protein 2-specific immunity in patients with cancer. / Kalli, Kimberly R.; Krco, Christopher J.; Hartmann, Lynn C.; Goodman, Karin; Maurer, Matthew J.; Yu, Chao; Johnson, Elliot M.; Erskine, Courtney L.; Disis, Mary L.; Wettstein, Peter J.; Fikes, John D.; Beebe, Melanie; Ishioka, Glenn; Knutson, Keith L.

In: Cancer Research, Vol. 68, No. 12, 15.06.2008, p. 4893-4901.

Research output: Contribution to journalArticle

Kalli, KR, Krco, CJ, Hartmann, LC, Goodman, K, Maurer, MJ, Yu, C, Johnson, EM, Erskine, CL, Disis, ML, Wettstein, PJ, Fikes, JD, Beebe, M, Ishioka, G & Knutson, KL 2008, 'An HLA-DR-degenerate epitope pool detects insulin-like growth factor binding protein 2-specific immunity in patients with cancer', Cancer Research, vol. 68, no. 12, pp. 4893-4901. https://doi.org/10.1158/0008-5472.CAN-07-6726
Kalli, Kimberly R. ; Krco, Christopher J. ; Hartmann, Lynn C. ; Goodman, Karin ; Maurer, Matthew J. ; Yu, Chao ; Johnson, Elliot M. ; Erskine, Courtney L. ; Disis, Mary L. ; Wettstein, Peter J. ; Fikes, John D. ; Beebe, Melanie ; Ishioka, Glenn ; Knutson, Keith L. / An HLA-DR-degenerate epitope pool detects insulin-like growth factor binding protein 2-specific immunity in patients with cancer. In: Cancer Research. 2008 ; Vol. 68, No. 12. pp. 4893-4901.
@article{1273043ec1c140f19ee012ec582fb4c9,
title = "An HLA-DR-degenerate epitope pool detects insulin-like growth factor binding protein 2-specific immunity in patients with cancer",
abstract = "Recent studies have shown the importance of helper CD4 T cells in initiating and sustaining tumor-specific CD8 T-cell immunity. This has paved the way for identifying MHC class II epitopes that could be incorporated into class I-based vaccines. In this study, the goal was to identify an HLA-DR-degenerate epitope pool derived from insulin-like growth factor binding protein 2 (IGFBP-2). IGFBP-2, a regulator of insulin-like growth factor action, is overexpressed in the majority of breast and ovarian cancers. Using algorithms, we predicted 29 HLA-DR1-binding epitopes. Binding assays targeting 15 different HLA-DRs revealed that 10 epitopes were degenerate, binding to at least four different HLA-DR variants. An IFN-γ enzyme-linked immunosorbent spot assay was used to assess immunity to these 10 epitopes in 48 patients with either breast or ovarian cancer and 18 controls. Elevated Tcell immunity in patients was detected in 4 of the 10 epitopes (IGFBP2.17, IGFBP2.22, IGFBP2.249, and IGFBP2.293). The cumulative T-cell frequency of these four epitopes was elevated in patients relative to controls. All four peptides are naturally processed and presented to CD4 T-cells. The degenerate pool of peptides covers nearly 80{\%} of patients and may be useful for augmenting CD4 T-cell immunity in patients undergoing immunization.",
author = "Kalli, {Kimberly R.} and Krco, {Christopher J.} and Hartmann, {Lynn C.} and Karin Goodman and Maurer, {Matthew J.} and Chao Yu and Johnson, {Elliot M.} and Erskine, {Courtney L.} and Disis, {Mary L.} and Wettstein, {Peter J.} and Fikes, {John D.} and Melanie Beebe and Glenn Ishioka and Knutson, {Keith L}",
year = "2008",
month = "6",
day = "15",
doi = "10.1158/0008-5472.CAN-07-6726",
language = "English (US)",
volume = "68",
pages = "4893--4901",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - An HLA-DR-degenerate epitope pool detects insulin-like growth factor binding protein 2-specific immunity in patients with cancer

AU - Kalli, Kimberly R.

AU - Krco, Christopher J.

AU - Hartmann, Lynn C.

AU - Goodman, Karin

AU - Maurer, Matthew J.

AU - Yu, Chao

AU - Johnson, Elliot M.

AU - Erskine, Courtney L.

AU - Disis, Mary L.

AU - Wettstein, Peter J.

AU - Fikes, John D.

AU - Beebe, Melanie

AU - Ishioka, Glenn

AU - Knutson, Keith L

PY - 2008/6/15

Y1 - 2008/6/15

N2 - Recent studies have shown the importance of helper CD4 T cells in initiating and sustaining tumor-specific CD8 T-cell immunity. This has paved the way for identifying MHC class II epitopes that could be incorporated into class I-based vaccines. In this study, the goal was to identify an HLA-DR-degenerate epitope pool derived from insulin-like growth factor binding protein 2 (IGFBP-2). IGFBP-2, a regulator of insulin-like growth factor action, is overexpressed in the majority of breast and ovarian cancers. Using algorithms, we predicted 29 HLA-DR1-binding epitopes. Binding assays targeting 15 different HLA-DRs revealed that 10 epitopes were degenerate, binding to at least four different HLA-DR variants. An IFN-γ enzyme-linked immunosorbent spot assay was used to assess immunity to these 10 epitopes in 48 patients with either breast or ovarian cancer and 18 controls. Elevated Tcell immunity in patients was detected in 4 of the 10 epitopes (IGFBP2.17, IGFBP2.22, IGFBP2.249, and IGFBP2.293). The cumulative T-cell frequency of these four epitopes was elevated in patients relative to controls. All four peptides are naturally processed and presented to CD4 T-cells. The degenerate pool of peptides covers nearly 80% of patients and may be useful for augmenting CD4 T-cell immunity in patients undergoing immunization.

AB - Recent studies have shown the importance of helper CD4 T cells in initiating and sustaining tumor-specific CD8 T-cell immunity. This has paved the way for identifying MHC class II epitopes that could be incorporated into class I-based vaccines. In this study, the goal was to identify an HLA-DR-degenerate epitope pool derived from insulin-like growth factor binding protein 2 (IGFBP-2). IGFBP-2, a regulator of insulin-like growth factor action, is overexpressed in the majority of breast and ovarian cancers. Using algorithms, we predicted 29 HLA-DR1-binding epitopes. Binding assays targeting 15 different HLA-DRs revealed that 10 epitopes were degenerate, binding to at least four different HLA-DR variants. An IFN-γ enzyme-linked immunosorbent spot assay was used to assess immunity to these 10 epitopes in 48 patients with either breast or ovarian cancer and 18 controls. Elevated Tcell immunity in patients was detected in 4 of the 10 epitopes (IGFBP2.17, IGFBP2.22, IGFBP2.249, and IGFBP2.293). The cumulative T-cell frequency of these four epitopes was elevated in patients relative to controls. All four peptides are naturally processed and presented to CD4 T-cells. The degenerate pool of peptides covers nearly 80% of patients and may be useful for augmenting CD4 T-cell immunity in patients undergoing immunization.

UR - http://www.scopus.com/inward/record.url?scp=49649084295&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49649084295&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-07-6726

DO - 10.1158/0008-5472.CAN-07-6726

M3 - Article

C2 - 18559537

AN - SCOPUS:49649084295

VL - 68

SP - 4893

EP - 4901

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 12

ER -